Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography
暂无分享,去创建一个
[1] J. Cummings,et al. Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates , 1988, Journal of geriatric psychiatry and neurology.
[2] J. Morris,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.
[3] J. Rinne,et al. Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra , 1989, Annals of neurology.
[4] A. Lees,et al. A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.
[5] D. Mann,et al. Amyloid beta protein (A beta) deposition in dementia with Lewy bodies: predominance of A beta 42(43) and paucity of A beta 40 compared with sporadic Alzheimer's disease. , 1998, Neuropathology and applied neurobiology.
[6] Mann,et al. Amyloid β protein (Aβ) deposition in dementia with Lewy bodies: predominance of Aβ42(43) and paucity of Aβ40 compared with sporadic Alzheimer’s disease , 1998 .
[7] J. Growdon,et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.
[8] P. Lantos,et al. Beta-Amyloid Deposition in the Temporal Lobe of Patients with Dementia with Lewy Bodies: Comparison with Non-Demented Cases and Alzheimer’s Disease , 2000, Dementia and Geriatric Cognitive Disorders.
[9] G. Glosser,et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease , 2000, Neurology.
[10] H. Ross,et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease , 2000, Neurology.
[11] D. Dickson,et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease , 2000, Acta Neuropathologica.
[12] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[13] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Copeland,et al. Progress towards testing the amyloid hypothesis: inhibitors of APP processing. , 2001, Current opinion in drug discovery & development.
[15] Glenda M. Halliday,et al. Cortical Lewy body pathology in the diagnosis of dementia , 2001, Acta Neuropathologica.
[16] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] Joseph E Parisi,et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. , 2002, Archives of neurology.
[18] F. Mastaglia,et al. Prevalence of amyloid‐β deposition in the cerebral cortex in Parkinson's disease , 2003 .
[19] William E. Klunk,et al. The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component , 2003, The Journal of Neuroscience.
[20] F. Mastaglia,et al. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. , 2003, Movement disorders : official journal of the Movement Disorder Society.
[21] K. Jellinger. Prevalence of Alzheimer lesions in Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.
[22] M. Emre. Dementia associated with Parkinson's disease , 2003, The Lancet Neurology.
[23] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[24] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[26] D. Aarsland,et al. Neuropathology of dementia in Parkinson's disease: A prospective, community‐based study , 2005, Annals of neurology.
[27] Lisa A. Weissfeld,et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.
[28] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[29] E. Perry,et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.
[30] M. Viitanen,et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease , 2006, Neurology.
[31] Keith A. Johnson,et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.
[32] Keith A. Johnson,et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. , 2007, Archives of neurology.
[33] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[34] E. Tolosa,et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[35] C. Rowe,et al. In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.
[36] Matthias Reimold,et al. [11C]PIB binding in Parkinson's disease dementia , 2008, NeuroImage.
[37] A. Verma,et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .
[38] C. Rowe,et al. Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[39] Keith A. Johnson,et al. Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.